Activation of the RAS/ERK and its downstream signaling components is essential for growth factor-induced cell survival, proliferation and differentiation. SHP2, encoded by Ptpn11, is a positive mediator required for most, if not all, receptor tyrosine kinase (RTK)-evoked RAS/ERK activation, but differentially regulates the PI3 kinase/AKT (PI-3K) signaling cascade in different cellular contexts. The precise mechanisms underlying differential effects of SHP2 deficiency on the PI-3K pathway remain unclear. We found that mice with myelomonocytic cellspecific (Tg(LysM-Cre);Ptpn11 fl/fl mice) Ptpn11 deficiency exhibit mild osteopetrosis. Ptpn11-/bone marrow macrophages (BMMs) showed decreased proliferation in response to macrophage colony stimulating factor (M-CSF) and decreased osteoclast generation. M-CSF-evoked ERK1/2 activation was decreased, while AKT activation was enhanced, in SHP2-deficient BMMs. ERK1/2, via its downstream target RSK2, mediates this negative feedback by negatively regulating phosphorylation of M-CSF receptor (M-CSFR) at Tyr721 and, consequently, its binding to p85 subunit of PI3K and PI3 kinase activation. Pharmacologic inhibition of RSK or ERK phenotypically mimics the signaling defects observed in SHP2-deficient BMM. Furthermore, this increase in PI3K/AKT activation enables BMM survival in the setting of SHP2 deficiency.
Introduction
Receptor tyrosine kinases (RTKs) regulate the growth, proliferation, differentiation and survival of multiple cell types during development and in adulthood. Despite their pleiotropic actions, RTKs typically initiate a limited and common set of downstream signaling events. Most RTKs activate RAS, which in turn triggers a kinase cascade consisting of one or more RAF family members, MEK1/2, ERK1/2, and ERK-dependent kinases, such as RSK family members (1-4).
Activated RAS also promotes the activation of class I phosphatidylinositol-3 kinases (PI-3Ks) (5) , as do proteins that bind the regulatory subunits (e.g., p85α/β) of class I PI-3Ks, which include some RTKs themselves and scaffolding adaptors, such as IRS (6) and GAB (7-9) family members.
The lipid products of PI-3K bind to PH domain-containing proteins and promote activation of the serine-threonine kinase AKT (and other PH-domain containing signaling components) (10) . RTKs also can bind to and activate phospholipase C-γ, SRC family kinases (SFKs) and/or STAT family transcription factors (11) .
A major question in RTK signal transduction is how activation such a restricted number of downstream pathways can result in such diverse effects. Differential recruitment/activation of signal relay molecules and the cellular context in which RTK activation occurs may explain some of the distinct effects of RTKs. Yet the mere number of RTKs and the paucity of downstream signaling cascades they evoke suggest that other mechanisms contribute to RTK specificity.
Several studies show that the kinetics of downstream pathway activation/inactivation are critical determinants of the biological response to RTK activation (12) . Consequently, elucidating the mechanisms that control pathway dynamics, including negative feedback pathways, is critical for a detailed understanding of RTK action.
Macrophage-colony stimulating factor (M-CSF) is essential for monocyte/macrophage and osteoclast proliferation, differentiation, viability and motility (13, 14) . Accordingly, op/op mice, which lack M-CSF, are deficient in most macrophage populations and develop severe osteopetrosis (15) . M-CSF signals via the Class III RTK, the M-CSFR (a.k.a., CSF1R, c-Fms), which, like other RTKs, binds multiple SH2 (and PTB) domain-containing signal relay molecules that activate canonical downstream signaling cascades. M-CSF-evoked RAS/ERK activation reportedly is mediated via binding of SFKs, GRB2, and CBL1 to M-CSFR-Tyr559, -Tyr697/Tyr921 and -Tyr973, respectively (16) (17) (18) (19) . M-CSF-induced PI3-K/AKT activation is evoked by p85 binding to M-CSFR-Tyr721 (17, 20) and to GAB family adaptor proteins (21, 22) . By contrast, M-CSFR-Tyr706 recruits and activates STAT1 , whereas c-CBL binding to Tyr973 promotes M-CSFR ubiquitination and subsequent lysosomal trafficking (23) and degradation (24, 25) . The prevailing model holds that the RAS/ERK pathway is important for M-CSF-evoked monocytic cell proliferation, whereas the PI3 kinase/AKT pathway promotes cell survival (13) and STAT1 activation is important for macrophage differentiation (26, 27) . There is, however, some disagreement over details: for example, some reports implicate ERK activation in differentiation as well as proliferation (28) , whereas others implicate PI-3K/AKT activation in proliferation in addition to survival (29) .
The SRC homology-2 domain-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is required for optimal RAS/ERK pathway activation in most, if not all, RTK, cytokine and integrin signaling pathways (30, 31) . SHP2 has variable effects on the PI-3K/AKT pathway: in at least some cell types, SHP2 negatively regulates EGF-evoked PI-3K/AKT activation by dephosphorylating the PI-3K binding sites on GAB1 (32, 33) . However, SHP2 is required for PI-3K activation downstream of other RTKs (34) (35) (36) . Moreover, SHP2 has cell type-and receptor-specific effects on STAT, RHO family GTPase, NF-kB and NFAT activation (31, 37, 38) . Reflecting its manifold effects on cell signaling, global Ptpn11 deletion in mice causes early embryonic lethality due to trophoblast stem cell death (39) , whereas post-natal SHP2 deletion has variably severe effects on the development and function of multiple cell and tissues (30, 31) .
ES cell differentiation and chimera experiments implicate SHP2 in the earliest stages of embryonic and adult hematopoiesis, yet less is known about its role in specific hematopoietic cells (40, 41) .
In monocyte/macrophage lineage cells, for example, SHP2 is found in a signaling protein complex evoked by M-CSF and associates with GAB family adaptor proteins upon M-CSF stimulation (21) .
Yet its precise role in M-CSF signaling, as well as its effects on monocyte/macrophages and osteoclasts in vivo have remained unknown (42) .
To address these issues, we generated mice with selective deletion of the Ptpn11 gene in monocyte/macrophages and osteoclasts. As in other RTK signaling systems, we find that SHP2 is required for RAS/ERK pathway activation, although monocyte/macrophage SHP2 deficiency has relatively minor effects, decreasing BMM proliferation and osteoclastogenesis. In the course of these studies, however, we uncovered a novel, ERK-mediated negative feedback pathway that controls phosphorylation of the M-CSFR on specific tyrosyl residues and thereby regulates the dynamics of M-CSF-evoked PI-3K/AKT activation. Loss of this feedback pathway (as a consequence of defective RAS/ERK activation) might mitigate the effect of SHP2 deficiency on monocyte/macrophage lineage cells and could provide potential escape mechanisms for cancer cells treated with SHP2 or MEK inhibitors.
MATERIALS AND METHORDS
Reagents M-CSF and GM-CSF were purchased from Peprotech Inc, and erythopoietin (EPO) was purchased from Janssen-Ortho Inc. UO126 and LY294002 were from Calbiochem, and rapamycin was from Sigma. The RSK inhibitor Fmk was synthesized as described previously (43) . Rabbit polyclonal antibodies against murine M-CSFR (c-Fms) were a gift from Dr. Sara A. Courtneidge (Sanford-Burnham Institute). Rabbit polyclonal antibodies against the C-terminus of M-CSFR, SHP2 and the p85 subunit of PI3-K were purchased from Santa Cruz Biotechnology, Inc., rabbit polyclonal antibodies against PKA substrates (R/KXXS/T), p-ERK1/2 (Try202Thr208), p-AKT (Ser473), p-p90RSK(Ser380), p-p70S6 kinase, p90RSK2, and p-M-CSFR (Tyr721) were from Cell Signaling Inc., monoclonal anti-phosphotyrosine antibodies (clone 4G10) were from Upstate Biotechnology, Inc., and anti-FLAG-epitope antibodies were purchased from Sigma. HRP-labeled anti-mouse and rabbit secondary antibodies and protein-A and G beads were purchased from Amersham Inc. For LICOR-based western blotting, goat anti-rabbit IR-Dye 800 and 680, goat anti-mouse IR-Dye 800 and 680 were purchased from LICOR. All antibodies were diluted in 1X TBS/5% non-fat milk for immunoblotting experiments. pMX(puro)-based constructs harboring EPO receptor (EPOR)/M-CSFR-WT (FLAG-epitope-tagged) were described previously (18 1A) . To trace the cell-fate of myelomonocytic cells in the SHP2mΦCTR and SHP2mΦKO mice in vivo and in vitro, Tg(Rosa26-ZsGreen1) reporter was crossed over to SHP2mΦCTR and SHP2mΦKO mice in some studies.
Cell culture BMMs from 6-9 week-old wild type (WT), SHP2mΦCTR, and SHP2mΦKO mice were derived and cultured for 7-9 days in DMEM containing 10% fetal bovine serum (FBS) and 1/100 volume of CMG14-12 culture supernatant, as described previously (18) . Plat-E packaging cells were cultured in the presence of puromycin and blasticidin, as described (47 transfection and used to infect BM cells seeded the previous day in the presence of M-CSF (10 ng/ml) and polybrene (4 µg/ml). Infected cells were subsequently cultured in M-CSF and 2µg/ml puromycin to select and expand transductants (18, 48) . Biochemical analyses BMMs were starved for 16h in DMEM supplemented with 0.2% FBS, and then stimulated with the indicated growth factors. After stimulation, cells were lysed in NP-40 buffer (0.5% NP40, 150 mM NaCl, 1 mM EDTA, 50 mM Tris, pH 7.4), supplemented with a protease inhibitor cocktail (1mM PMSF, 1 mM NaF, 1 mM sodium orthovanadate, 10 g/ml aprotinin, 0.5 g/ml antipain, and 0.5 g/ml pepstatin). Immunoprecipitations (IPs) were performed on cleared lysates, as described previously (39) . For immunoblotting, TCLs (30-50 µg)
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were resolved by SDS-PAGE, transferred to PVDF membranes, and incubated with primary antibodies at 4°C for 2 hours-overnight (according to the manufacturer's instructions), followed by HRP-conjugated secondary antibodies or goat anti-rabbit/mouse IR-Dye 800 or -600 antibodies for 1 hour. Detection was by enhanced chemiluminescence (Amersham) or LICOR scanning.
For immune complex PI-3K assays, M-CSFR immunoprecipitates from starved and M-CSF-stimulated BMMs were washed and subjected to lipid kinase assay, as described (49) .
Reactions were terminated by adding 200 μl of 1 N hydrochloric acid (HCl), extracted with 200 μl methanol/chloroform (1:1), and 50 μl of the organic phase were resolved by thin layer chromatography (TLC) in methanol/chloroform/H2O/NH4OH (20:23:4:1) on LK6D plates (Whatman). Plates were exposed to X-ray film, and phospholipid species were identified by co- 52 ). Peptide-based kinase assays also were performed as described (53) .
RESULTS

Generation of mice with conditional Ptpn11 deletion in myelomonocytic cells Global SHP2
deficiency causes embryonic lethality in mice (39, 54, 55) . To assess the role of SHP2 in macrophages, we crossed our Ptpn11 floxed allele (44) to Tg(LysM-Cre) mice (46) . As expected, SHP2 levels were reduced by ~50% and >90% in BMMs from SHP2mΦCTR and SHP2mΦKO mice, respectively, compared with wild type control levels (Fig. 1A) . No truncation variants were detected by immunoblotting with antibodies directed against either the N-or C-terminus of SHP2 (44) .
SHP2 is required for myelomonocytic cell proliferation but not for differentiation
SHP2mΦKO mice were born at the expected Mendelian ratio and appeared healthy. Blood counts and differentials, measured at 6-8 weeks of age, were comparable in SHP2mΦCTR and SHP2mΦKO mice. Preliminary experiments showed that there was no difference in phenotype between wild type, SHP2mΦCTR (hemizygous) and Ptpn11 fl/fl or Tg(LysM-Cre) parental mice; consequently, we used SHP2mΦCTR and SHP2mΦKO mice for most experiments. BMMs (Fig. 1B) , as well as cells from bone marrow (BM), spleen and peritoneal cavity of SHP2mΦKO mice (Fig. S1 ), showed normal expression of myelomonocytic cell surface markers, indicating that macrophage differentiation was unaffected by SHP2 deficiency. Likewise, cells from M-CSF-dependent colonies (CFU-M) showed normal monocytic morphology (Fig. 1C) . By contrast, the number and size of CFU-M were reduced in SHP2mΦKO mice, suggesting that SHP2 is required for optimal M-CSF-driven proliferation (Fig. 1C) . Indeed, proliferation in response to a saturating dose of M-CSF was impaired in SHP2mΦKO BMMs. M-CSF responsiveness also was diminished, as indicated by a rightward shift in dose-response curve (Fig. 1D) . Consistent with these data and the monocyte/macrophage origin of osteoclasts, SHP2mΦKO mice showed defective osteoclastogenesis in response to M-CSF and RANKL in vitro and developed mild osteopetrosis at >7 months of age (Fig. 1E) . We conclude that SHP2 is required for optimal proliferation of macrophage progenitors, but is dispensable for their differentiation to mature macrophage populations. SHP2 also contributes to the generation of optimal levels of osteoclasts.
SHP2 deficiency impairs RAS/ERK activation but enhances the PI3-K/AKT pathway To
explore the molecular basis for defective proliferation of SHP2-deficient BMMs, we assayed known M-CSF-evoked signaling pathways. BMMs from SHP2mΦCTR and SHP2mΦKO mice were starved for 16 hours, and then stimulated with M-CSF (30 ng/ml). As expected, SHP2mΦCTR
BMMs showed robust and sustained activation of RAS (assayed by GST-Raf-RBD binding) and ERK (adjudged by immunoblotting with phospho-specific antibodies). By contrast (but similar to the effects of SHP2 deficiency in many other RTK and cytokine signaling pathways; see Introduction), RAS and ERK activation were transient in SHP2mΦKO BMMs ( Fig. 2A) . In control BMMs, AKT activation (assessed by Ser473 phosphorylation) peaked at 5 min., and then declined to basal levels by 30 min. In SHP2mΦKO BMMs, however, AKT activation was enhanced and sustained. These differences in ERK and AKT activation could not be explained by altered M-CSFR (c-Fms) levels: surface M-CSFR (CD115) expression ( Fig. 1B) was unaffected by SHP2 deficiency, and M-CSFR protein, assessed by immunoblotting, declined at a comparable rate following M-CSF stimulation of SHP2mΦCTR and SHP2mΦKO BMMs. SHP2 deficiency also had no effect on M-CSF-evoked STAT3 or STAT1 activation (Fig. S2A ).
SHP2 negatively regulates EGF-induced AKT activation by dephosphorylating the p85 binding site on the adaptor protein GAB1 (32, 33, 56, 57) . Surprisingly, PI-3K activity associated with GAB2, the major GAB family member in BMMs, was unaffected in SHP2-deficient BMMs (Fig. 2B) . PI-3 kinase also binds directly to the M-CSFR (17, 20) , and indeed, M-CSFR-associated PI-3K activity was enhanced and sustained in SHP2mΦKO BMMs (Fig. 2C) . This increase was accompanied by a slight increase in overall tyrosyl phosphorylation of M-CFSR (Fig. 2D, left panel) and a more substantial increase in phosphorylation of the binding site (Tyr721) for p85 on the receptor (17, 20) ( Fig. 2E ). M-CSFR/p85 association also was enhanced (Fig. 2D, right panel). Taken together, these findings strongly suggest that increased AKT activation in SHP2deficient BMMs is due to increased M-CSFR phosphorylation on its binding site for p85.
SHP2 regulates M-CSFR tyrosyl phosphorylation indirectly, via its effect on ERK activation.
The simplest explanation for the above results would be that SHP2 dephosphorylates Tyr721 (and perhaps other sites) on the M-CSFR. However, SHP2 does not associate with the M-CSFR, nor did we find evidence for SHP2-catalyzed dephosphorylation of the receptor. We wondered whether increased M-CSF-evoked PI-3K/AKT activity in SHP2-deficient BMMs might be the indirect consequence of their defective ERK activation. Indeed, whereas pre-treatment of wild type BMMs with the PI-3K/mTOR inhibitor LY294002 blocked M-CSF-evoked AKT activation, the MEK inhibitor UO126 enhanced AKT activation (Fig. 3A, Fig. S2C ). This effect was receptorspecific, as MEK inhibition did not affect AKT activation in response to GM-CSF ( Fig. 3B) .
Similar to the effects of SHP2 deficiency, UO126 pre-treatment resulted in increased M-CSFevoked PI-3K activation, increased phosphorylation of Tyr721 and increased association of p85
with the M-CSFR (Fig. 3C, D) .
Previous studies of other cell types and RTK signaling pathways have shown that ERK or the ERK-activated kinase RSK (1) can phosphorylate and inhibit TSC2, thereby promoting mTOR activity. mTOR, in turn, activates p70S6 kinase (p70S6K), which can inhibit PI-3K/AKT activation via a well-known negative feedback loop (58, 59) . However, treatment of BMMs with rapamycin, which inhibits TORC1 (and p70S6K) activation, did not enhance AKT phosphorylation (Fig. S2B) , extents similar to that evoked by UO126 treatment (Fig. 4) .
Inspection of the M-CSFR cytoplasmic domain revealed two highly conserved serine residues that fall within consensus motifs for RSK phosphorylation; interestingly, these motifs, YVRRDS 711 G and MRPVS 728 T, also flank Tyr721 (Fig. 5A) . Despite substantial effort, we were unable to map RSK-dependent phosphorylation sites on the M-CSFR in vivo, most likely because the tryptic peptides containing the putative sites did not fly well in mass spectrometry experiments.
However, recombinant human RSK2 phosphorylated the M-CSFR cytoplasmic domain in vitro ( Fig. 5B) . Therefore, as an alternative approach to identifying RSK phosphorylation sites, we generated a peptide array spanning the entire M-CSFR cytoplasmic domain, and assessed the ability of recombinant RSK2 to phosphorylate these peptides. Remarkably, only peptides containing Ser711 were phosphorylated by RSK2, whereas Ser711>Ala-substituted peptides were refractory to phosphorylation (Fig. 5C ). Fig. 6A ) Importantly, the WT and S711A chimeras were expressed at comparable levels, as revealed by anti-FLAG immunoblotting, and M-CSF-evoked AKT activation was sustained in cells expressing the S711A mutant, consistent with its increased Tyr721 phosphorylation (Fig. S4A) How RSK controls Tyr721 phosphorylation remains unclear. Fig. 7) . AKT inhibition decreased the percentage of SHP2mΦCTR BMMs in S phase by ~50%, but did not increase the number of sub-G1 (apoptotic) cells. By contrast, under normal growth conditions, SHP2mΦKO BMMs showed a ~2-fold fewer S and G2/M cells, and a slightly increased number of sub-G1 cells, consistent with their decreased proliferation rate. Addition of the AKT inhibitor (10 µM) caused a further, ~3-fold decrease in S phase cells, and evoked substantial apoptosis, with the sub-G1 population rising to ~19% in SHP2mΦKO (compared with ~2% in SHP2mΦCTR) BMMs. These data suggest that increased activation of the PI-3K/AKT pathway in SHP2mΦKO BMMs (as a consequence of impaired RSKmediated negative feedback) helps to protect them from the decrease in proliferation and survival that would ordinarily accompany defective RAS/ERK pathway activation. Consistent with this notion, combined inhibition of the RAS/ERK and PI3-K/AKT pathways in WT BMMs (by treatment with UO126 and LY294002) causes a dramatic increase in cell death (Fig. S5) ,
Phosphorylation of Ser711 does not influence the phosphorylation of
Loss of the ERK/RSK-mediated negative feedback loop promotes survival of SHP2-deficient BMM but has minimal effect on cytokine production
comparable to the effects of AKT inhibition in SHP2-deficient BMM (Fig. 7A) .
Discussion
SHP2 is a key mediator of signaling by most, if not all RTKs and cytokine receptors (30, 31 ), yet its role in specific hematopoietic lineages remains largely unexplored. By studying the effects of selective deletion of a "floxed" Ptpn11 allele in the presence of a LysM-Cre transgene, we found that SHP2, while dispensable for myelomonocytic differentiation, is required for optimal proliferation of monocyte/macrophage progenitors. Because these progenitors also give rise to osteoclasts, SHP2 is required for efficient osteoclast production in vitro, and SHP2mΦKO mice develop mild osteopetrosis as they age. In attempting to elucidate the molecular basis for these mild defects, we identified a novel negative feedback pathway in which the ERK-dependent kinase RSK2 regulates the phosphorylation of the binding site for p85 on the M-CSFR, Tyr721, and possibly other tyrosyl residues (Fig. 6B) . This feedback pathway, in turn, controls the extent and SHP2-deficient BMMs show increased AKT activity, which, by analogy to studies of other signaling pathways (32, 33, 57) , we initially expected to be due to increased GAB binding to p85.
However, GAB2-associated PI-3K activity (and p85 association) is comparable in SHP2mΦCTR and SHP2mΦKO BMMs. Instead, we find that M-CSFR-associated PI-3K activation is enhanced in SHP2mΦKO BMMs, as a consequence of increased M-CSFR Tyr721 phosphorylation and p85 recruitment.
Several lines of evidence suggest that an indirect, RSK-mediated negative feedback pathway (Fig. 6B) inhibitors and suggesting that of the four known RSK family members (1), RSK2 specifically mediates this negative feedback pathway (Fig. 4B) . Second, GM-CSF-evoked AKT activation is unaffected by SHP2 deficiency, which suggests that receptor-proximal events are involved in the negative regulatory mechanism. Although RSK can phosphorylate M-CSFR on Ser711 in vitro, and Ser711 phosphorylation controls the extent and duration of Tyr721 phosphorylation,
immunoblotting experiments indicate that Ser711 is constitutively phosphorylated. Furthermore, UO126 treatment does not affect Ser711 phosphorylation (Fig. S4B) . Therefore, the RSKmediated negative feedback pathway must be mediated by another, as yet unidentified protein, and Ser711 must be phosphorylated by another kinase. Protein kinase A is a good candidate for the latter, because BMMs, treated with PKA activator 8-Bromo cAMP, show reduced tyrosyl phosphorylation of M-CSFR (67).
Our findings have important implications for understanding macrophage and osteoclast regulation by M-CSFR, for RTK signaling in general, and for the potential use of MEK inhibitors for cancer therapeutics. The concomitant loss of the RSK2-mediated feedback pathway probably helps explain the relatively mild effects of impaired RAS/ERK activation in the monocyte/macrophage lineage. Consistent with this notion, SHP2mΦKO BMMs are strongly sensitized to PI3K or AKT inhibitor treatment (Fig. 7A) . It is increasingly clear that the duration and magnitude of downstream pathway activation are key determinants of signal specificity by RTKs and other types of receptors. Feedback pathways probably play an important role in regulating these pathway properties. In this regard, the RSK2-mediated pathway that we have identified is reminiscent of the now well-characterized p70S6K-catalyzed negative feedback regulation of insulin/insulin-like growth factor receptor signaling (4, 58) . Finally, the RAS/ERK pathway is up-regulated in many tumors, which has prompted the development of MEK-inhibitors 
